SEC Form 4 · accession 0001144204-16-105769
Arch Therapeutics, Inc. · ARTH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James R Sulat
Director
Period of report
May 26, 2016
Accepted (ET)
May 31, 2016 · 1:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001537561
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | May 26, 2016 | P$0 | 111,111 | — | A | 868,934 | I | See Footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series E Warrant to Purchase Common StockF1,F2,F3 | $0.438 | May 26, 2016 | P | 83,333 | A | May 26, 2016 | May 26, 2021 | Common Stock | 83,333 | 83,333 | I |
Explanation of responses
- F1The Common Stock and Series E Warrants reported on this Form 4 were sold in the form of Units issued by Arch Therapeutics, Inc. in a private placement conducted on May 26, 2016 at a price of $0.36 per Unit. Each Unit consisted of one share of Common Stock and a Series E Warrant to purchase 0.75 Shares of Common Stock at an exercise price of $0.438 per share.
- F2Held indirectly by the Keyes Sulat Revocable Trust, of which Mr. Sulat and his spouse are the trustees and the members of Mr. Sulat's immediately family are the beneficiaries.
- F3Of the shares of Common Stock underlying the Series E Warrants, all are immediately exercisable.